This post has been archived and contains information that may be out of date.
Despite warnings from the Food and Drug Administration, manufacturers and various patient safety agencies, fentaNYL transdermal patches continue to be prescribed inappropriately to treat patients with acute pain and who are not opioid tolerant.
Recognizing this as an ongoing issue, the CHA Medication Safety Committee created a High Alert Medication Guideline – FentaNYL Transdermal Patch is attached. The guideline summarizes safe-use practices; however, it should be considered only a guideline. Hospitals should consult with their hospital pharmacy and therapeutics committee prior to implementing the guideline.
